Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics
This article was originally published in The Pink Sheet Daily
Executive Summary
Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.
You may also be interested in...
Melinta To Launch First Commercial Drug Baxdela Independently
Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but Baxdela will face challenges in a market dominated by generics.
Financings Of The Fortnight And The Never-Ending Venture Round
While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.